Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 3/20 | 0.54 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 11/20 | 0.38 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL29081916 | 0.83 | PRMT5 (0.54) | PRMT5WDR77RIPK1FFAR2SIGMAR1 | |
| SCHEMBL29477756 | 0.77 | PRMT5 (0.54) | PRMT5WDR77RIPK1CHRNB2CHRNB4 | |
| SCHEMBL29081332 | 0.75 | PRMT5 (0.47) | PRMT5WDR77RIPK1FFAR2 | |
| Lithium Ion SCHEMBL30470962 | 0.74 | PRMT5 (0.54) | PRMT5WDR77RIPK1 | |
| SCHEMBL24364491 | 0.71 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL24365449 | 0.71 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL24364492 | 0.71 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL24363971 | 0.71 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL24367242 | 0.71 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL24367170 | 0.71 | PRMT5 (1.00) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | PRMT5 347/4885WDR77 1263/4885RIPK1 4522/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | PRMT5 3142/4885WDR77 3960/4885RIPK1 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.